Acceleron
Cambridge, Massachusetts, United States
Acceleron was a biopharmaceutical therapies company acquired by Merck in 2021.
How We Help
Problem Statement
Acceleron aimed to address significant unmet medical needs in various hematologic, neuromuscular, and pulmonary diseases, including anemia and Pulmonary Arterial Hypertension, by developing novel biotherapeutics that modulate crucial cell and tissue growth and repair processes.
Core Technology
Exploiting the therapeutic potential of the transforming growth factor beta (TGF-β) superfamily of proteins by developing novel agonists and antagonists to modulate the growth of bone, muscle, fat, and vasculature.
Key Differentiators
Leadership in understanding TGF-beta biology and protein engineering, enabling the development of first-in-class therapies with novel mechanisms of action, such as REBLOZYL and sotatercept.
Clinical Focus
Hematologic, neuromuscular, and pulmonary diseases.
Target Customers
Pharmaceutical companies (for partnerships and licensing) and ultimately patients through their therapeutic products.
Product Stage
GA/Mature (for REBLOZYL) and late-stage development (for sotatercept).
Company Info
- Business Model
- B2B, focused on discovery, development, and commercialization of biotherapeutics, generating revenue through collaboration, licensing, and research arrangements with partners like Celgene (now Bristol Myers Squibb).
- Founded
- 2003
- Total Funding
- 493,000,000
- Website
- acceleronpharma.com
Categories
Disease Areas
Technologies
Clinical & IP
Clinical Validation
A clinical-stage biopharmaceutical company that developed drugs like Luspatercept/REBLOZYL (used for anemia) and Sotatercept (a key asset for Pulmonary Arterial Hypertension), demonstrating successful clinical development and market entry for some products.
IP Protection
Leveraged intellectual property as part of its business model, contributing to its value proposition and strategic partnerships.
MedStartr Index Score
?What do you think of Acceleron?
A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.